文献速递中枢神经肿瘤放疗放疗物理与技术

化学交换饱和转移成像评估胶质母细胞瘤治疗反应

Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-04

研究纳入19例新诊断胶质母细胞瘤患者,在标准6周放化疗前(第0天)、第14天、第28天及治疗结束后1个月(第70天)行化学交换饱和转移(CEST)-MRI。第0天至第14天MTRNOE和MTRAmide变化能最佳区分非进展者与进展者,且基线MTRNOE、MTRAmide、MT和CESTNOE可在治疗前识别进展者。

要点

  • CEST-MRI可在治疗2周时提供胶质母细胞瘤治疗反应的影像生物标志物。
  • 第0天至第14天MTRNOE和MTRAmide变化最佳区分非进展者与进展者。
  • 基线MTRNOE、MTRAmide、MT和CESTNOE可在治疗前识别进展者。

核心结论

  • CEST可在治疗2周时提供胶质母细胞瘤治疗反应的影像生物标志物。
  • 某些CEST指标可在治疗开始前表征肿瘤侵袭性并识别早期进展者。
  • 这种早期反应生物标志物可能有助于对早期进展者调整胶质母细胞瘤治疗方案以行适应性放疗,并对非进展者更有信心地继续标准辅助治疗。

研究设计与样本

  • 研究纳入19例新诊断胶质母细胞瘤患者,在治疗前(第0天)、治疗2周(第14天)、治疗4周(第28天)及治疗结束后1个月(第70天)采集CEST-MRI。
  • 评估的CEST指标包括磁化转移率及对应核奥弗豪泽效应(NOE)和酰胺质子的CEST峰曲线下面积(分别为MTRNOE、MTRAmide、CESTNOE和CESTAmide)、磁化转移(MT)和直接水效应。
  • 早期进展缺失定义为根据放化疗后常规系列结构MRI无肿瘤增大或临床症状恶化。

主要发现

  • 基线(第0天)至第14天MTRNOE变化:非进展者1.35±0.18 vs 进展者0.97±0.22,P=.006。
  • 基线(第0天)至第14天MTRAmide变化:非进展者1.25±0.17 vs 进展者0.99±0.10,P=.017。
  • 基线(第0天)MTRNOE:非进展者6.5%±1.6% vs 进展者9.1%±2.1%,P=.015。
  • 基线(第0天)MTRAmide:非进展者6.7%±1.7% vs 进展者8.9%±1.9%,P=.028;MT:非进展者3.8%±0.9% vs 进展者5.4%±1.4%,P=.019。
  • 基线(第0天)CESTNOE:非进展者4.1%·Hz±1.7%·Hz vs 进展者6.1%·Hz±1.9%·Hz,P=.044。

临床怎么用

  • 作者认为,这种早期反应生物标志物可能允许对早期进展者调整胶质母细胞瘤治疗方案以行适应性放疗,并对非进展者更有信心地继续标准辅助治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To monitor cellular and metabolic characteristics of glioblastoma (GBM) over the course of standard 6-week chemoradiation treatment with chemical exchange saturation transfer (CEST)-MRI; and to identify the earliest time point CEST could determine subsequent therapeutic response. METHODS AND MATERIALS: Nineteen patients with newly diagnosed GBM were recruited, and CEST-MRI was acquired immediately before (Day0), 2 weeks (Day14) and 4 weeks (Day28) into treatment, and 1 month after the end of treatment (Day70). Several CEST metrics, including magnetization transfer ratio and area under the curve of CEST peaks corresponding to nuclear Overhauser effect (NOE) and amide protons (MTRNOE, MTRAmide, CESTNOE, and CESTAmide respectively), magnetization transfer (MT), and direct water effect were investigated. Lack of early progression was determined as no increase in tumor size or worsening of clinical symptoms according to routine post-chemoradiation serial structural MRI. RESULTS: Changes in MTRNOE (nonprogressors = 1.35 ± 0.18, progressors = 0.97 ± 0.22, P = .006) and MTRAmide (nonprogressors = 1.25 ± 0.17, progressors = 0.99 ± 0.10, P = .017) between baseline (Day0) and Day14 resulted in the best separation of nonprogressors from progressors. Moreover, the baseline (Day0) MTRNOE (nonprogressors = 6.5% ± 1.6%, progressors = 9.1% ± 2.1%, P = .015), MTRAmide (nonprogressors = 6.7% ± 1.7%, progressors = 8.9% ± 1.9%, P = .028), MT (nonprogressors = 3.8% ± 0.9%, progressors = 5.4% ± 1.4%, P = .019), and CESTNOE (nonprogressors = 4.1%ċHz ± 1.7%ċHz, progressors = 6.1%ċHz ± 1.9%ċHz, P = .044) were able to identify progressors even before the start of the treatment. CONCLUSIONS: Chemical exchange saturation transfer (CEST) provides imaging-based biomarkers of GBM response as early as 2 weeks into the treatment. Certain CEST metrics can characterize tumor aggressiveness and identify early progressors even before beginning the treatment. Such an early biomarker of response may allow for adjusting the GBM treatment plan for adaptive radiation therapy in early progressors and more confidently continuing standard adjuvant treatment for nonprogressors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mehrabian H, Myrehaug S, Soliman H, et al. Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29893279. doi:10.1016/j.ijrobp.2018.03.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。